obesity drug news today glp-1 october 2025 Outlook for obesity in 2025: more than a transition year Rhode Island considers ending Medicaid

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Rossi, A

Drugs like Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda, Victoza) are not only changing the way we manage Type 2 Diabetes but also making waves in the weight-loss industry

Drug repurposing: progress, challenges and recommendations

Various guidelines have been proposed to mitigate the risk of adverse events, which includes avoiding initiation in those at extremes of age, recent history of DKA and frequent history of severe fungal infection [30]